A World Without
Vir’s COVID-19 Treatment Authorized for Emergency Use in the United States
We are proud to announce sotrovimab (previously known as VIR-7831), our investigational monoclonal antibody, has been granted Emergency Use Authorization by the U.S. Food and Drug Administration for the treatment of mild-to-moderate COVID-19 in high-risk adults and pediatric patients.
Infectious diseases are among the leading causes of death worldwide.
Vir is focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases.
A new era
Remarkable advances have improved our understanding of pathogens and the immune system.
Our four current technology platforms are designed to, either individually or in combination, stimulate and enhance the immune system by exploiting critical observations of natural immune processes.
To prevent, treat, and cure
We are taking aim at some of the world’s largest and most serious infectious diseases, infections that are evasive, challenging, or insufficiently addressed by current approaches including COVID-19, hepatitis B, influenza A and HIV.